

PRIOR AUTHORIZATION POLICY

POLICY: Oncology – Tibsovo Prior Authorization Policy

- Tibsovo® (ivosidenib tablets –Servier/Les)

REVIEW DATE: 03/06/2024

OVERVIEW

Tibsovo, an isocitrate dehydrogenase-1 (IDH1) inhibitor, is indicated for the treatment of cancers with a susceptible *IDH1* mutation as detected by an FDA-approved test:¹

- **Acute myeloid leukemia, newly diagnosed disease, in combination with azacitidine or as monotherapy**, in patients who are ≥ 75 years of age or who have comorbidities that preclude use of intensive induction chemotherapy.
- **Acute myeloid leukemia, relapsed or refractory disease**, in adults.
- **Cholangiocarcinoma, locally advanced or metastatic**, in adults who have been previously treated.
- **Myelodysplastic syndrome, relapsed or refractory disease**, in adults.

Guidelines

Tibsovo is discussed in the National Comprehensive Cancer Network (NCCN) guidelines:²

- **Acute Myeloid Leukemia:** NCCN guidelines (version 1.2024 – February 28, 2024) recommend Tibsovo as a single-agent (category 2A) as “Other Recommended Regimen” or in combination with azacitidine (category 1) as “Preferred” therapy for treatment induction for patients with an *IDH1* mutation who are not candidates for intensive induction therapy; and it is also used for follow-up after induction therapy, and consolidation therapy for patients with an *IDH1* mutation. Tibsovo is also recommended for relapsed or refractory disease with *IDH1* mutation (category 2A).³
- **Bone Cancer:** NCCN guidelines (version 1.2024 – August 7, 2023) recommend Tibsovo for conventional (grades 1 to 3) and dedifferentiated chondrosarcoma in patients with susceptible *IDH1* mutations as “Useful in Certain Circumstances” (category 2A).⁵
- **Central Nervous System Cancers:** NCCN guidelines (version 1.2023 – March 24, 2023) recommend Tibsovo for recurrent or progressive *IDH-1* mutant oligodendroglioma World Health Organization (WHO) grade 2 as “Other Recommend Regimens” and WHO grade 3 as “Useful in Certain Circumstances” (both category 2A) and *IDH-1* mutant astrocytoma WHO grade 2 as “Other Recommended Regimens” (category 2A) and WHO grade 3 or 4 as “Useful in Certain Circumstances” (category 2B).⁶
- **Cholangiocarcinoma:** NCCN guidelines for biliary tract cancer (version 3.2023 – November 8, 2023) cite Tibsovo as “Useful in Certain Circumstances” for patients with cholangiocarcinoma with *IDH1* mutations as subsequent-line therapy if there is disease progression (category 1).⁴
- **Myelodysplastic Syndromes:** NCCN guidelines (version 1.2024 – February 12, 2024) recommend Tibsovo for patients with myelodysplastic syndrome with *IDH 1* o mutation when patients has not experienced a response to other therapies.⁷

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Tibsovo. All approvals are provided for the duration noted below.

Automation: None.

03/06/2024

© 2024. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Tibsovo is recommended in those who meet one of the following criteria:

FDA-Approved Indications

- 1. Acute Myeloid Leukemia.** Approve for 1 year if the patient meets the following (A and B):
 - A) Patient is ≥ 18 years of age; AND
 - B) Patient has isocitrate dehydrogenase-1 (*IDH1*) mutation-positive disease as detected by an approved test.
- 2. Cholangiocarcinoma.** Approve for 1 year if the patient meets the following (A, B and C):
 - A) Patient is ≥ 18 years of age; AND
 - B) Patient has isocitrate dehydrogenase-1 (*IDH1*) mutation-positive disease; AND
 - C) Patient has been previously treated with at least one chemotherapy regimen.
Note: Examples are gemcitabine + cisplatin; Imfinzi (durvalumab intravenous infusion) + gemcitabine + cisplatin, 5-fluorouracil + oxaliplatin or cisplatin; capecitabine + oxaliplatin or cisplatin; gemcitabine + Abraxane (paclitaxel protein-bound particles intravenous infusion) or capecitabine or oxaliplatin; and FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin).
- 3. Myelodysplastic Syndrome.** Approve for 1 year if the patient meets the following (A, B, and C):
 - A) Patient is ≥ 18 years of age; AND
 - B) Patient has isocitrate dehydrogenase-1 (*IDH1*) mutation-positive disease; AND
 - C) Patient has relapsed or refractory disease.

Other Uses with Supportive Evidence

- 4. Bone Cancer.** Approve for 1 year if the patient meets the following (A and B):
 - A) Patient has chondrosarcoma; AND
 - B) Patient has isocitrate dehydrogenase-1 (*IDH1*) mutation-positive disease.
- 5. Central Nervous System Cancer.** Approve for 1 year if the patient meets the following (A, B and C):
 - A) Patient is ≥ 18 years of age; AND
 - B) Patient has recurrent or progressive disease; AND
 - C) Patient has meets one of the following (i or ii):
 - i. Patient has World Health Organization (WHO) grade 2 or 3 oligodendroglioma; OR
 - ii. Patient has WHO grade 2 astrocytoma.

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Tibsovo is not recommended in the following situations:

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES

1. Tibsovo® tablets [prescribing information]. Boston, MA: Servier; October 2023.
2. The NCCN Drugs & Biologics Compendium. © 2024 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on March 4, 2024. Search term: ivosidenib.

03/06/2024

© 2024. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

3. The NCCN Acute Myeloid Leukemia Clinical Practice Guidelines in Oncology (version 1.2024 – February 28, 2024). © 2024 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on March 4, 2024.
4. The NCCN Biliary Tract Cancers Clinical Practice Guidelines in Oncology (version 3.2023 – November 8, 2023). © 2023 National Comprehensive Cancer Network, Inc. Available at: <http://www.nccn.org>. Accessed on March 4, 2024.
5. The NCCN Bone Cancers Clinical Practice Guidelines in Oncology (version 1.2024 – August 7, 2023). © 2023 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on March 4, 2024.
6. The NCCN Central Nervous System Cancers Clinical Practice Guidelines in Oncology (version 1.2023 – March 24, 2023). © 2023 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on March 4, 2024.
7. The NCCN Myelodysplastic Syndromes Clinical Practice Guidelines in Oncology (version 1.2024 – February 12, 2024). © 2024 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on March 4, 2024.